HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Waseem Hajjar Khaled Al-Kattan Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by El-Medany, Y. Articles by Ashour, M. Search for Related Content PubMed PubMed Citation Articles by El-Medany, Y. Articles by Ashour, M. Related Collections Mediastinum

Predictors of Outcome for Myasthenia Gravis after Thymectomy

Thoracic Surgery Unit, Department of Surgery, King Khalid University Hospital, King Saud University, Riyadh, Kingdom of Saudi Arabia

For reprint information contact: Mahmoud Ashour, FRCS Tel: 966 1 467 1575 Fax: 966 1 467 9493 email: mashour90{at}hotmail.com Thoracic Surgery Division, Department of Surgery (37), King Khalid University Hospital, College of Medicine, P.O. Box 7805, Riyadh 11472, Kingdom of Saudi Arabia.

The aim of this study was to assess the clinical outcome of patients with myasthenia gravis treated with maximal thymectomy and to identify prognostic variables that predict the outcome. Over 15 years, from 1986 to 2001, we collected data on 100 patients with myasthenia gravis who underwent maximal thymectomy and retrospectively reviewed their outcome. Women comprised 63% and the median age was 25 years (range, 4 to 61). The median duration of the disease was 26 months (range, 1 to 240). According to the Osserman classification, there were seven patients in class I, 31 in class II, 47 in class III, and 15 in class IV. In non thymomatous patients (93 patients), complete remission rate progressively increased from 37.4% to 58.2% and 75% at 3, 10 and 15 years of follow-up respectively. These findings suggest that the complete remission rate is prone to increase with time after maximal thymectomy. The total benefit rate achieved was estimated to be 86% while 14% did not improve at a mean follow-up period of 7.6 years (range, 8 to 180 months). Univariate analysis (p < 0.05) showed that age, thymic histology and ectopic thymic tissue are significant prognostic factors for outcome.

This article has been cited by other articles:

				H. El-Bawab, W. Hajjar, M. Rafay, A. Bamousa, A. Khalil, and K. Al-Kattan Plasmapheresis before thymectomy in myasthenia gravis: routine versus selective protocols Eur. J. Cardiothorac. Surg., March 1, 2009; 35(3): 392 - 397. [Abstract] [Full Text] [PDF]

				J. M. Ponseti, J. Gamez, R. Vilallonga, C. Ruiz, J. Azem, M. Lopez-Cano, and M. Armengol Influence of ectopic thymic tissue on clinical outcome following extended thymectomy in generalized seropositive nonthymomatous myasthenia gravis Eur. J. Cardiothorac. Surg., November 1, 2008; 34(5): 1062 - 1067. [Abstract] [Full Text] [PDF]

				H. El-Bawab, A. A. Al-Sugair, M. Rafay, W. Hajjar, M. Mahdy, and K. Al-Kattan Role of flourine-18 fluorodeoxyglucose positron emission tomography in thymic pathology Eur. J. Cardiothorac. Surg., April 1, 2007; 31(4): 731 - 736. [Abstract] [Full Text] [PDF]

				J. W. Rubin Invited commentary. Ann. Thorac. Surg., September 1, 2006; 82(3): 1007 - 1008. [Full Text] [PDF]